Device Trial Radar · NCT03085433
Sperm Selection by Microfluidic Separation Improves Embryo Quality
Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
393
Actual
Start
Jun 20, 2017
Primary completion
Oct 30, 2021
Study completion Apr 30, 2022
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 21, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized controlled trial of couples with a history of poor embryo quality undergoing a repeat in vitro fertilization (IVF) cycle for unexplained infertility. Couples will be randomized to sperm selection by the clinical standard of centrifugation and density-gradient processing compared to the microfluidic sperm sorting chip.
Conditions
- Sperm DNA Fragmentation
- Embryo Quality
- Fertility Disorders
- Infertility
- Infertility, Male
- Infertility Unexplained
Interventions
Microfluidic Sperm SortingDevice
Microfluidic technology isolates healthy sperm by laminar flow, creating gradients through channels. The microfluidic chip we plan to study in our randomized clinical trial utilizes space-constrained microfluidic sorting to select highly motile and morphologically normal sperm in a flow and chemical-free design. Unlike the standard of density gradient centrifugation, no manipulation of sperm is required in this process. Raw semen is introduced into the inflow and only motile and morphologically normal sperm are able to swim through the chip to the outflow where it is collected for use.
in vitro fertilizationProcedure
ivf/icsi
Primary outcomes
What the sponsor says the trial is designed to measure.
- Day 3 High Quality Embryo PercentageTime frame: 3 days following fertilization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.